Last month, the FDA Office of Prescription Drug Promotion announced they will be conducting a discrete choice experiment study to understand how both patients and physicians weigh attributes of potential treatments.

With the growing emphasis putting the patient at center of policy development and value assessment, watch as Meaghan Roach explains how PRECISIONheor thinks about stakeholder insights and the role of primary data collection in gaining invaluable insights on the patient experience.

Interested in learning more? Check out more articles below written by PRECISIONheor experts on this topic:

• The Complementary Relationship Between Quantitative and Qualitative Research Methods in Enhancing Understanding of Treatment Decisions, Outcomes, and Value Assessment
• The Importance of Qualitative Research in Enhancing Understanding of Treatment Decisions, Outcomes, and Value Assessment